Cediranib Azd2171 CAS 288383-20-0 for Anti-Tumor Drug

Basic Info.

Product Name:AZD2171; Recentin(CAS No: 288383-20-0)

Synonyms:Cediranib;4-(4-Fluoro-2-methylindol-5-yloxy)-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quinazoline;Cadiranib(AZD2171);Cediranib(AZD2171);AZD2171;Recentin;Cadiranib;Cediranib R

M. Wt: 435.08 

Formula: C25H27FN4O3 

Solubility: 10 mmol/L in DMSO 

Purity: 98% 

Storage: -20C

Shelf life:2 years 

Reference FOB Price:$1/g

MOQ:10g

Specification:ISO9001,USP,BP,GMP

Trade Mark:CQSP

Port:Shenzhen/Shanghai,China

Production Capacity:5000kg/month

Shipping: DHL, EMS, FedEx, UPS

More details pls contact:Whatapp:86 13048470428  

Skype/E-mail : summer at chembj.com

Description:

Cediranib is a highly potent inhibitor of VEGFR with IC50 value of <1 nM.

Cediranib (tentative trade name Recentin), also known as AZD2171, is a potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases. It is a inhibitor with IC50 of <1 nM, also inhibits Flt1/4 with IC50of 5 nM/≤3 nM, similar activity against c-Kit and PDGFRβ, 36-, 110-fold and >1000-fold selective more for VEGFR than PDGFR-α, CSF-1R and Flt3, Phase 2/3.

It is being developed by AstraZenecaas a possible anticancer chemotherapeutic agent for oral administration.

Cediranib COA

Item Specification 

Specific rotation +39.5 to +41.5° 

State of solution(transmittance) Clear 98.0% min.

Chloride[cl] 0.020% max. 

Ammonium [NH4] 0.02% max. 

Sulfate[SO4] 0.020% max

Iron[Fe] 10ppm max.

Heavy metals [Pb] 10ppm max

Arsenic[As2O3] 1ppm max

Other amino acids Chromatographically not detectable

Loss on drying 0.20% max. 

Residue on ignition[sulfated] 0.10% max.

Assay 99.0% min

Application

Cediranib inhibition of bFGF and EGF when an IC50 of 0.5 and 0.11 μM. In the MG63 cell lines, Cediranib inhibiting PDGF-AA, IC50 of 0.04 μM. Cediranib Flt-1 associated kinase inhibition, IC50 of 5 nM, Cediranib inhibition of VEGF-C and VEGF-D receptor Flt-4, IC50 of less than 3 nM. [1] In addition, cediranib inhibition of c-Kit and PDGFR-β tyrosine kinase, IC50 were 2 and 5 nM. In vitro, micromolar concentrations cediranib can directly inhibit the proliferation of tumor cells. Sub nanomolar Cediranib blocking tubules produced, and inhibits VEGF-induced angiogenesis in vivo.